Back To Search Results


Editor: Muhammad Aziz Updated: 8/14/2023 10:52:51 PM


Gastric acid is the fluid secreted by the stomach. It is composed of hydrochloric acid, potassium chloride, and sodium chloride. Hydrochloric acid plays an integral part in the digestion of food and protects our body against pathogens ingested with food or water. The parietal cells lining the stomach are mainly involved in its production. Achlorhydria or hypochlorhydria refers to conditions in which the production of hydrochloric acid in the stomach is respectively absent or reduced. It is usually secondary to an underlying medical condition.[1][2]


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care


Multiple disorders can cause achlorhydria.[3][4][5]

  • Pernicious anemia (anti-parietal and anti-intrinsic factor antibodies): It is an autoimmune phenomenon in which antibodies are formed. These autoantibodies cause the autoimmune destruction of parietal cells leading to atrophic gastritis.
  • Use of antisecretory medications: Short-term standard dose treatment with proton pump inhibitors (PPIs) has been shown to have low risk, but long-term use of PPIs has been linked to hypochlorhydria.
  • Helicobacter pylori infection: Acute H. pylori infection of gastric epithelial cells represses H-K-ATPase alpha-subunit gene expression leading to transient hypochlorhydria and supporting H. pylori proliferation. This growth of H. pylori may even initiate a pathological process causing gastric cancer.
  • Gastric bypass: Gastric bypass is a gastric exclusion operation performed in patients with morbid obesity to reduce food intake. Studies show that the acid secretion unbuffered by the food in the excluded stomach results in lowered gastrin secretion hence leading to achlorhydria in such patients.
  • VIPomas: VIPoma is an endocrine tumor that usually arises from beta-pancreatic cells and secretes vasoactive intestinal peptide (VIP). It may be associated with multiple endocrine neoplasia type 1 (MEN1). The massive amounts of VIP secretion cause watery diarrhea, hypokalemia, achlorhydria, vasodilation, hypercalcemia, and hyperglycemia.
  • Hypothyroidism: Thyroid hormone plays a role in hydrochloric acid secretion; hence hypothyroidism can lead to achlorhydria.
  • Radiation to stomach: Radiation to the stomach has also been reported to cause achlorhydria.
  • Gastric cancer: Animal studies have shown evidence of achlorhydria in gastric cancer.


A study conducted on healthy people and patients with gastrointestinal (GI) diseases showed an increased incidence of achlorhydria and hypochlorhydria in women, but the results were not significant. In patients younger than 60 years of age, the incidence of achlorhydria and hypochlorhydria were 2.3% and 2%, respectively, whereas, in older patients, it increased to 5%. That is an increase of almost 3-fold. Another study on autoimmune causes showed an age-related incidence of parietal cell autoantibodies. Their prevalence increases with age, for example, from 2.5% in the third decade to 12% in the eighth decade. Autoimmune gastritis is frequently found in association with other autoimmune conditions. It is also a component of autoimmune polyglandular syndrome type 3. No association has been found between pernicious anemia and HLA types.[6][7][8]


Parietal cells lining the stomach wall are vital in maintaining the acidic pH of the stomach. They do this with the help of a hydrogen potassium ATPase pump (HKA pump) which pushes potassium out and hydrogen back into the stomach. To keep the pump working, potassium ions must enter back into the stomach through the apical membrane. The apical membrane is lined with potassium-selective channels that are responsible for potassium ion efflux. These are called inward rectifier channels (Kir). A study conducted on knockout mice showed genetic evidence of one such channel: KCNE2-KCNQ1. KCNQ1 is a transmembrane voltage-gated, homotetrameric potassium-selective channel. KCNE2 alters the voltage dependence of KCNQ1, converting it to a voltage-independent gate that has increased current conduction at low pH. KCNE2 and KCNQ1 are often found at the apical membrane of parietal cells. Targeted gene deletion of either of these subunits was found to result in achlorhydria. This study showed that these play an essential role in gastric acid secretion by maintaining the supply of luminal potassium to keep the HK-ATPase pump functional. In the same study, dysfunction of KCNQ1 also caused the development of gastric neoplasia independent of H. Pylori infection (secondary to achlorhydria). Thus any insult to parietal cells by any means (antibodies, surgery, drugs) can lead to achlorhydria which further activates multiple cascades of events that can lead to bacterial proliferation, GI symptoms, and even gastric cancer.


Studies have shown evidence of changes in oxyntic mucosa in longstanding autoimmune gastritis. The oxyntic mucosa is mainly composed of parietal cells, activation of which increases acid production in the stomach. The oxyntic mucosa undergoes four distinctive yet overlapping histological changes:

  • In the early phase, the plasma cells and lymphocytes migrate into the lamina propria, and patchy destruction of oxyntic cells may be seen. 
  • The lymphocytes and plasma cells then form dense infiltrate in the lamina propria. A metaplastic process is observed in the oxyntic cells; the large pale staining oxyntic cells are replaced by a new phenotype of clear cells, also known as pseudo-pyloric metaplasia.
  • Then follows intestinal metaplasia of gastric glands, which can later lead to malignancy.
  • In advanced gastritis, atrophy of oxyntic mucosa is seen. There can also be fibrosis, polyp formation, hyperplasia of muscularis mucosae, and/or enterochromaffin-like cells.

History and Physical

Depending on the primary cause, the symptoms of achlorhydria can vary. Generally, patients develop the following symptoms, which are listed in order of their prevalence:

  • Epigastric pain
  • Weight loss
  • Heartburn
  • Nausea
  • Bloating
  • Diarrhea
  • Abdominal pain
  • Acid regurgitation
  • Early satiety
  • Vomiting
  • Postprandial fullness
  • Constipation
  • Dysphagia
  • Glossitis
  • Decreased position and vibration sense


When suspecting achlorhydria, multiple tests are conducted to confirm the diagnosis and to find its primary cause:

  • Antiparietal and anti-intrinsic factor antibody
  • Biopsy of stomach
  • Gastric pH monitoring
  • Serum pepsinogen level (a low serum pepsinogen level indicates achlorhydria)
  • Serum gastrin levels (high serum gastrin levels greater than 500 to 1000 pg/mL may indicate achlorhydria)
  • Tests for detecting H. pylori infection (urea breath test, stool antigen test, biopsy, polymerase chain reaction-PCR, or fluorescent in situ hybridization [FISH]) 
  • Hemoglobin level

Treatment / Management

There is no specific treatment for achlorhydria. Eradication of H. pylori is recommended in patients who are found to have it. Other treatments are targeted at improving the complications of achlorhydria.[9][10][11] These include the replacement of calcium, vitamin D, iron, and vitamin B12. There are no specific guidelines for surveillance, although it is a preneoplastic condition. The Kyoto consensus in 2015 stated that endoscopic surveillance and follow-up should be done in patients who underwent eradication therapy for H. pylori and were found to have a preneoplastic condition.(B3)

Differential Diagnosis

  • Mucolipidosis type IV
  • Pernicious anemia
  • VIPomas


Despite having a risk of developing into gastric adenocarcinoma and gastric carcinoid tumor, achlorhydria has a good prognosis.


The majority of the complications found in achlorhydria are due to nutrient deficiency. They are also more common compared to the other complications.

  • Iron deficiency
  • Vitamin-B12 deficiency
  • Vitamin-D and calcium deficiency leading to osteoporosis and bone fracture
  • Gastric adenocarcinoma
  • Gastric carcinoid tumor
  • Small intestinal bacterial overgrowth syndrome

Deterrence and Patient Education

Patients are educated that due to increased gastric pH, some drugs will not be absorbed effectively thus, such drugs are given in higher doses.

Pearls and Other Issues

  • Anything that causes an insult to the parietal cells can lead to the development of achlorhydria.
  • KCNE2 and KCNQ1 were found to play a significant role in the functioning of parietal cells by a knockout study conducted in mice.
  • Despite leading to some malignant conditions (a rare occurrence) in the stomach, achlorhydria has a good prognosis.
  • No specific guidelines have been established for long-term surveillance.
  • The treatment varies on the underlying cause and is mainly directed at the replacement of nutrient deficiency.

Enhancing Healthcare Team Outcomes

Achlorhydria is not a very common disorder in clinical practice. Even when it presents, the signs and symptoms are vague. However, in order to avoid high morbidity, healthcare workers, including the primary care provider, must consider it in the differential diagnosis when evaluating patients with epigastric discomfort. The pharmacist should assist with pain control. To make the diagnosis of achlorhydria, testing is always required. Once the diagnosis is made, the treatment depends on the cause. Even though there are no current guidelines on screening or monitoring of these patients, the clinician should always be aware that cases of gastric cancer have been reported in these patients. [Level 5][12][13]



Li Y, Xia R, Zhang B, Li C. Chronic Atrophic Gastritis: A Review. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer. 2018:37(3):241-259. doi: 10.1615/JEnvironPatholToxicolOncol.2018026839. Epub     [PubMed PMID: 30317974]


Furuta T, Baba S, Yamade M, Uotani T, Kagami T, Suzuki T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Alimentary pharmacology & therapeutics. 2018 Aug:48(3):370-377. doi: 10.1111/apt.14849. Epub 2018 Jun 19     [PubMed PMID: 29920721]


Chen C, Zheng Z, Li B, Zhou L, Pang J, Wu W, Zheng C, Zhao Y. Pancreatic VIPomas from China: Case reports and literature review. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2019 Jan:19(1):44-49. doi: 10.1016/j.pan.2018.10.007. Epub 2018 Oct 26     [PubMed PMID: 30391116]

Level 3 (low-level) evidence


Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Giusti F, Marini F, Brandi ML. Multiple Endocrine Neoplasia Type 1. GeneReviews(®). 1993:():     [PubMed PMID: 20301710]


Belei OA, Heredea ER, Boeriu E, Marcovici TM, Cerbu S, Mărginean O, Iacob ER, Iacob D, Motoc AGM, Boia ES. Verner-Morrison syndrome. Literature review. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. 2017:58(2):371-376     [PubMed PMID: 28730220]


Villanacci V, Casella G, Lanzarotto F, Di Bella C, Sidoni A, Cadei M, Salviato T, Dore MP, Bassotti G. Autoimmune gastritis: relationships with anemia and Helicobacter pylori status. Scandinavian journal of gastroenterology. 2017 Jun-Jul:52(6-7):674-677. doi: 10.1080/00365521.2017.1288758. Epub 2017 Feb 17     [PubMed PMID: 28276835]

Level 3 (low-level) evidence


Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L, Syrjänen K. Prevalence of H. pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers. Anticancer research. 2013 Oct:33(10):4595-602     [PubMed PMID: 24123036]


Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nature reviews. Gastroenterology & hepatology. 2013 Sep:10(9):529-41. doi: 10.1038/nrgastro.2013.101. Epub 2013 Jun 18     [PubMed PMID: 23774773]


Tytgat GN. Review article: Practical management issues for the Helicobacter pylori-infected patient at risk of gastric cancer. Alimentary pharmacology & therapeutics. 1998 Feb:12 Suppl 1():123-8     [PubMed PMID: 9701009]


Glasbrenner B, Eissele R, Heeckt P, Klatt S, Beger HG, Adler G. [Multicentric gastric carcinoid in autoimmune gastritis]. Deutsche medizinische Wochenschrift (1946). 1996 Feb 23:121(8):231-6     [PubMed PMID: 8815022]

Level 3 (low-level) evidence


Lechner K, Födinger M, Grisold W, Püspök A, Sillaber C. [Vitamin B12 deficiency. New data on an old theme]. Wiener klinische Wochenschrift. 2005 Sep:117(17):579-91     [PubMed PMID: 16395986]


Kayamba V, Shibemba A, Zyambo K, Heimburger DC, Morgan DR, Kelly P. High prevalence of gastric intestinal metaplasia detected by confocal laser endomicroscopy in Zambian adults. PloS one. 2017:12(9):e0184272. doi: 10.1371/journal.pone.0184272. Epub 2017 Sep 8     [PubMed PMID: 28886101]


Castoro C, Le Moli R, Arpi ML, Tavarelli M, Sapuppo G, Frittitta L, Squatrito S, Pellegriti G. Association of autoimmune thyroid diseases, chronic atrophic gastritis and gastric carcinoid: experience from a single institution. Journal of endocrinological investigation. 2016 Jul:39(7):779-84. doi: 10.1007/s40618-016-0445-5. Epub 2016 Feb 29     [PubMed PMID: 26928404]